---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-088455"
form_type: "8-K"
ticker: "BCYC"
cik: "0001761612"
company_name: "BICYCLE THERAPEUTICS PLC"
filed_at: "2026-07-30T11:05:32+00:00"
generated_at: "2026-07-30T11:10:33.126322+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Bicycle Therapeutics Q2 net loss $50.3M ($0.72/share); cash $510.1M; clinical progress on nuzefatide and zelenectide

## Summary
- Net loss of $50.3M ($0.72 per share) for Q2 2026, compared to $79.0M ($1.14) in Q2 2025.
- Cash and equivalents of $510.1M as of June 30, 2026; expected cash runway into 2030.
- R&D expenses fell to $41.2M from $71.0M, driven by workforce reduction and lower zelenectide costs.
- First patient dosed in Phase 2 trial of nuzefatide in recurrent pancreatic cancer in April 2026.
- Expanded Clinical Advisory Board with Thomas Powles, MD, a leader in urothelial cancer.

## SEC filing metadata
- accession: 0001104659-26-088455
- form_type: 8-K
- ticker: BCYC
- cik: 0001761612
- company_name: BICYCLE THERAPEUTICS PLC
- filed_at: 2026-07-30T11:05:32+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1761612/000110465926088455/0001104659-26-088455-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1761612/000110465926088455/tm2621593d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-088455
- JSON: https://secwatch.observer/filing/0001104659-26-088455.json
- Plain text: https://secwatch.observer/filing/0001104659-26-088455.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.